New blood thinning drug reduces second stroke risk without increasing bleeding risk

A major international clinical trial has raised new hope for millions of stroke survivors worldwide, suggesting that a new investigational drug may significantly reduce the risk of a second stroke without increasing dangerous bleeding complications.

The drug, asundexian, has shown promising results in a large Phase 3 study published in The New England Journal of Medicine, pointing toward a possible shift in how recurrent ischemic stroke could be prevented in the future.

A major global health challenge

Recurrent stroke remains a serious medical concern. Nearly 1 in 4 patients who survive an initial stroke may experience another episode, making long-term prevention a critical priority in neurology and cardiovascular care.

Current treatments such as antiplatelet and anticoagulant therapies are widely used to reduce clot formation. While effective, they come with a significant limitation — an increased risk of bleeding, including potentially life-threatening brain hemorrhage.

This long-standing treatment dilemma has driven the search for safer alternatives.

How asundexian works differently

Asundexian belongs to a new class of oral anticoagulants that target Factor XIa, a protein involved in the clotting cascade.

Unlike traditional blood thinners that interfere with broader clotting pathways, Factor XIa inhibition is designed to selectively reduce harmful clot formation while preserving normal blood clotting needed to stop bleeding.

Experts involved in the study explain that this mechanism may allow the body to maintain essential hemostasis while reducing pathological thrombosis that leads to stroke.

Major findings from a global Phase 3 trial

The OCEANIC-STROKE Phase 3 trial involved more than 12,300 participants across 37 countries, making it one of the largest studies of its kind in secondary stroke prevention.

Participants included individuals who had recently experienced an ischemic stroke or high-risk transient ischemic attack (TIA). They were randomly assigned to receive either asundexian alongside standard antiplatelet therapy or a placebo with standard treatment.

Key findings included:
• 26 percent reduction in recurrent ischemic stroke risk
• No increase in major or intracranial bleeding
• Reduction in disabling or fatal strokes
• Consistent benefits across age, gender, and stroke subtypes

Researchers also reported an absolute risk reduction of 1.9 percent over one year, suggesting meaningful clinical benefit when added to standard care.

Why these results matter for patients

Stroke specialists say these findings are important because they suggest a new category of treatment that may reduce the risk of recurrence without introducing the major safety concern that limits current therapies.

Currently, aspirin and similar drugs remain the backbone of long-term prevention for most ischemic stroke patients. However, experts believe Factor XIa inhibitors like asundexian could represent the first major advancement in decades for broader secondary stroke prevention.

Still investigational but highly promising

Despite encouraging outcomes, researchers emphasize that asundexian is still not approved for clinical use. Further regulatory review and additional studies will be required before it can be prescribed to patients.

Experts also note that certain patient groups were underrepresented in the trial, meaning broader real-world validation will be important.

However, early evidence suggests that the drug could be especially useful for patients at high risk of recurrence who cannot tolerate stronger anticoagulants due to bleeding concerns.

A step toward safer long-term stroke protection

If future studies confirm these findings, asundexian could mark a significant shift in stroke prevention strategy by offering protection against clot formation without the traditional trade-off of increased bleeding risk.

For now, the medical community views the results as a promising step forward in the ongoing effort to make stroke prevention both safer and more effective.

---

Stay informed, stay alert

CLICK HERE TO JOIN Medical News Pakistan on WhatsApp for real-time health alerts, expert insights, and breakthrough medical discoveries.